AU2014274982B2 - Compositions and methods for conjugating activatable antibodies - Google Patents

Compositions and methods for conjugating activatable antibodies Download PDF

Info

Publication number
AU2014274982B2
AU2014274982B2 AU2014274982A AU2014274982A AU2014274982B2 AU 2014274982 B2 AU2014274982 B2 AU 2014274982B2 AU 2014274982 A AU2014274982 A AU 2014274982A AU 2014274982 A AU2014274982 A AU 2014274982A AU 2014274982 B2 AU2014274982 B2 AU 2014274982B2
Authority
AU
Australia
Prior art keywords
activatable antibody
seq
agent
antibody
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014274982A
Other languages
English (en)
Other versions
AU2014274982A1 (en
Inventor
Luc Roland DESNOYERS
Andrei William KONRADI
Tony W. Liang
Henry Bernard LOWMAN
Shweta SINGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytomx Therapeutics Inc
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of AU2014274982A1 publication Critical patent/AU2014274982A1/en
Application granted granted Critical
Publication of AU2014274982B2 publication Critical patent/AU2014274982B2/en
Priority to AU2020201405A priority Critical patent/AU2020201405A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2014274982A 2013-06-04 2014-06-04 Compositions and methods for conjugating activatable antibodies Ceased AU2014274982B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020201405A AU2020201405A1 (en) 2013-06-04 2020-02-26 Compositions and methods for conjugating activatable antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361830913P 2013-06-04 2013-06-04
US61/830,913 2013-06-04
US201361919935P 2013-12-23 2013-12-23
US61/919,935 2013-12-23
PCT/US2014/040931 WO2014197612A1 (en) 2013-06-04 2014-06-04 Compositions and methods for conjugating activatable antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201405A Division AU2020201405A1 (en) 2013-06-04 2020-02-26 Compositions and methods for conjugating activatable antibodies

Publications (2)

Publication Number Publication Date
AU2014274982A1 AU2014274982A1 (en) 2015-12-10
AU2014274982B2 true AU2014274982B2 (en) 2019-12-05

Family

ID=51023194

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014274982A Ceased AU2014274982B2 (en) 2013-06-04 2014-06-04 Compositions and methods for conjugating activatable antibodies
AU2020201405A Abandoned AU2020201405A1 (en) 2013-06-04 2020-02-26 Compositions and methods for conjugating activatable antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020201405A Abandoned AU2020201405A1 (en) 2013-06-04 2020-02-26 Compositions and methods for conjugating activatable antibodies

Country Status (10)

Country Link
US (4) US9517276B2 (enExample)
EP (1) EP3003387A1 (enExample)
JP (2) JP6660294B2 (enExample)
KR (1) KR20160018579A (enExample)
CN (2) CN116063479A (enExample)
AU (2) AU2014274982B2 (enExample)
BR (1) BR112015030514A2 (enExample)
CA (1) CA2913732A1 (enExample)
RU (1) RU2015156888A (enExample)
WO (1) WO2014197612A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
RU2713121C2 (ru) 2012-04-27 2020-02-03 Сайтомкс Терапьютикс, Инк. Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения
CN116063479A (zh) * 2013-06-04 2023-05-05 西托姆克斯治疗公司 用于缀合可活化抗体的组合物和方法
CA2918795A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
MX2016005763A (es) 2013-11-06 2016-08-19 Stemcentrx Inc Anticuerpos anti-claudina novedosos y metodos de uso.
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
AU2014361856A1 (en) 2013-12-12 2016-06-30 Abbvie Stemcentrx Llc Novel anti-DPEP3 antibodies and methods of use
WO2015127407A1 (en) 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
CN107108738A (zh) 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3244907B1 (en) 2015-01-13 2020-02-19 City of Hope Ctla4-binding protein peptide-linker masks
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016164370A1 (en) * 2015-04-06 2016-10-13 Ohio State Innovation Foundation Egfr-directed car therapy for glioblastoma
MX388350B (es) 2015-05-04 2025-03-19 Cytomx Therapeutics Inc Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
JP2018518972A (ja) * 2015-06-26 2018-07-19 ユニバーシティ オブ サザン カリフォルニア 腫瘍特異的活性化のためのマスキングキメラ抗原受容体ｔ細胞
CN106519037B (zh) * 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 可活化的嵌合受体
PL3377103T5 (pl) 2015-11-19 2025-07-07 Revitope Limited Komplementacja funkcjonalnego fragmentu przeciwciała dla dwuskładnikowego układu do przekierowanego zabijania niepożądanych komórek
CN105267982A (zh) * 2015-11-20 2016-01-27 暨南大学 一种rhHER2抗体与MMAE偶联物及其制备方法与应用
RU2749715C2 (ru) 2016-02-29 2021-06-16 Регенерон Фармасьютикалз, Инк. Грызуны, характеризующиеся гуманизированным геном tmprss
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
EP3454900A4 (en) * 2016-05-09 2020-01-29 Celgene Corporation CD47 ANTIBODIES AND METHODS OF USE
JP2020500900A (ja) 2016-12-09 2020-01-16 シアトル ジェネティクス インコーポレーテッド コイルドコイルでマスキングされた二価抗体
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
AU2018328291B2 (en) 2017-09-08 2022-10-27 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
AU2018347607B2 (en) 2017-10-14 2025-08-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
CN108484781B (zh) * 2018-04-23 2021-05-04 深圳市国创纳米抗体技术有限公司 一种纳米抗体与铜绿假单胞菌外毒素的融合蛋白及应用
MX2020012248A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CN112912110A (zh) * 2018-06-12 2021-06-04 安吉克公司 抗体-寡核苷酸缀合物
SG11202013248YA (en) 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN120248140A (zh) 2018-12-06 2025-07-04 西托姆克斯治疗公司 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
WO2020164561A1 (en) 2019-02-15 2020-08-20 Wuxi Biologics (Shanghai) Co. Ltd. Process for preparing antibody-drug conjugates with improved homogeneity
WO2020176672A1 (en) * 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
JP2022524338A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 拘束され、条件的に活性化された結合タンパク質
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
EP4058471A1 (en) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP4087613A1 (en) * 2020-01-06 2022-11-16 Cytomx Therapeutics Inc. Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2023521384A (ja) 2020-04-09 2023-05-24 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能抗体を含む組成物
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
US20230408498A1 (en) * 2020-10-13 2023-12-21 Cz Biohub Sf, Llc Compositions and methods involving antibody constructs
WO2023070353A1 (en) * 2021-10-27 2023-05-04 Adagene Pte. Ltd. Anti-cd47 antibodies and methods of use thereof
EP4554625A1 (en) 2022-07-12 2025-05-21 CytomX Therapeutics, Inc. Epcam immunoconjugates and uses thereof
CN120058950A (zh) * 2023-11-28 2025-05-30 昆山新蕴达生物科技有限公司 抗adam9的抗体及其用途
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071441A2 (en) * 2004-11-30 2006-07-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
WO2009025846A2 (en) * 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US7837980B2 (en) * 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2013192550A2 (en) * 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
WO2013192546A1 (en) * 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
WO2014052462A2 (en) * 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PL2489364T3 (pl) 2003-11-06 2015-06-30 Seattle Genetics Inc Związki monometylowaliny zdolne do sprzęgania do przeciwciał
BRPI0612529A2 (pt) 2005-06-20 2010-11-23 Psma Dev Company Llc conjugados de anticorpo-medicamento de psma
CA2620886C (en) 2005-08-31 2017-03-14 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
WO2007105027A1 (en) 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
JP2012511033A (ja) 2008-12-08 2012-05-17 テゴファーム コーポレーション 多価化合物の可逆阻害用マスキングリガンド
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
CA2930801C (en) 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
MY170719A (en) 2011-04-01 2019-08-27 Wyeth Llc Antibody-drug conjugates
US20130066055A1 (en) 2011-04-21 2013-03-14 Bayer Intellectual Property Gmbh New binder-drug conjugates (adcs) and use thereof
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
PH12014500932A1 (en) * 2011-11-11 2014-06-09 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
SI2780039T1 (en) 2011-11-17 2018-06-29 Pfizer Inc. Cytotoxic peptides and their conjugates between the antibody and the drug
MX353608B (es) * 2012-02-24 2018-01-19 Alteogen Inc Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo.
WO2014004694A1 (en) 2012-06-26 2014-01-03 Massachusetts Institute Of Technology Reversible masking of pore-forming proteins for macromolecular delivery
CA2884299A1 (en) * 2012-10-24 2014-05-01 Polytherics Limited Novel drug-protein conjugates
WO2014107599A2 (en) 2013-01-04 2014-07-10 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
CN116063479A (zh) * 2013-06-04 2023-05-05 西托姆克斯治疗公司 用于缀合可活化抗体的组合物和方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7837980B2 (en) * 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2006071441A2 (en) * 2004-11-30 2006-07-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
WO2009025846A2 (en) * 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2013192550A2 (en) * 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
WO2013192546A1 (en) * 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
WO2014052462A2 (en) * 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHERKAOUI S ET AL, "Tracking of antibody reduction fragments by capillary gel electrophoresis during the coupling to microparticles surface", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 53, no. 2, pages 172 - 178, (2010-02-01) *
DONALDSON JOSHUA M ET AL, "Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies", CANCER BIOLOGY & THERAPY, (2009-11), vol. 8, no. 22, ISSN 1538-4047, pages 2147 - 2152 *
NATARAJAN A ET AL, "CHARACTERIZATION OF SITE-SPECIFIC SCFV PEGYLATION FOR TUMOR-TARGETING PHARMACEUTICALS", BIOCONJUGATE CHEMISTRY, (2005), vol. 16, no. 1, doi:10.1021/BC0498121, ISSN 1043-1802, pages 113 - 121 *
ORAN ERSTER ET AL, "Site-specific targeting of antibody activitymediated by disease-associated proteases", JOURNAL OF CONTROLLED RELEASE, vol. 161, no. 3, (2012-05-17), pages 804 - 812, (2012-05-23) *

Also Published As

Publication number Publication date
JP2016521707A (ja) 2016-07-25
RU2015156888A3 (enExample) 2018-05-30
JP2020079292A (ja) 2020-05-28
WO2014197612A9 (en) 2015-03-19
RU2015156888A (ru) 2017-07-14
US20170072067A1 (en) 2017-03-16
KR20160018579A (ko) 2016-02-17
CA2913732A1 (en) 2014-12-11
US11992528B2 (en) 2024-05-28
US20150005477A1 (en) 2015-01-01
US20250099606A1 (en) 2025-03-27
AU2020201405A1 (en) 2020-03-12
CN105658240A (zh) 2016-06-08
JP6660294B2 (ja) 2020-03-11
US20220088192A1 (en) 2022-03-24
BR112015030514A2 (pt) 2017-08-29
US9517276B2 (en) 2016-12-13
EP3003387A1 (en) 2016-04-13
WO2014197612A1 (en) 2014-12-11
AU2014274982A1 (en) 2015-12-10
CN116063479A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
US20250099606A1 (en) Compositions and methods for conjugating activatable antibodies
US12459999B2 (en) Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
US20250011439A1 (en) Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US20240076374A1 (en) Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
US10233244B2 (en) Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
US20180303952A1 (en) Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
EP4029880A1 (en) Activatable anti-cd71 antibodies, and methods of use thereof
HK40038123A (en) Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
HK1250036B (en) Activatable anti-cd166 antibodies, and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired